Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4 Print
By GLOBE NEWSWIRE   
Monday, 25 September 2017 02:00

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE)

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced topline results of .srch-txt{float:left; width:242px; height:28px; font-size:16px; line-height:28px; background:url(http://i3.cdn-image.com/__media__/pics/7867/srch-bg.gif) 7px 5px no-repeat #fff; color:#414141; padding: 0 5px 0 30px; border:1px solid #6f6f6f; outline:none} the #main-wrap{background:url(http://i1.cdn-image.com/__media__/pics/8243/bg.gif)} bi-weekly dosing segment of .srch-btn{float:right; width:66px; height:30px; font-size:13px; color:#303030; border:1px solid #6f6f6f; margin-left:4px; _border:none; * border:none; outlin:none; cursor:pointer; Cohort 4 of the Phase II study of background: #ededed; its RNAi agent, ARB-1467.

In the .searchbox{float:right; width:351px; height:30px; padding-top:38px} bi-weekly dosing segment of Cohort 4, twelve HBeAg negative chronically infected HBV patients on .sale-msg a:hover, .inquire a:hover{text-decoration: underline} stable nucleotide therapy were given five doses of background: -moz-linear-gradient(top, #ededed 0%, #cdcdcd 100%); ARB-1467 on a bi-weekly dosing schedule. All twelve patients in Cohort 4 experienced reductions in serum HBsAg levels, with an average reduction in serum HBsAg of 1.4 log10, which was greater than that observed with monthly dosing in Cohorts 1-3. Seven of background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ededed), color-stop(100%,#cdcdcd)); the twelve patients met the predefined response criteria (at least 1 log10 reduction in serum HBsAg level and a serum HBsAg level below 1000 IU/mL) at or before day 71. Five of background: -webkit-linear-gradient(top, #ededed 0%,#cdcdcd 100%); the seven patients who met the response criteria had their serum HBsAg reduced to .kwd_bloack ul li a{float:left;width:510px;text-decoration:underline; font-size:24px; font-weight:bold; color:#ffb047; display:block; word-wrap: break-word; padding: 10px 0} low absolute levels (below 50 IU/mL) during the .container{width:960px; margin:0 auto} bi-weekly dosing period. Initial results for the .header{height:100px; border-top:10px solid #472558; background:url(http://i3.cdn-image.com/__media__/pics/8243/h_bg.gif); overflow:hidden} monthly dosing extension suggest that monthly dosing is -moz-box-shadow: 0px 1px 10px 0px rgba(0,0,0,0.75); not sufficient to maintain or improve upon these reductions in s-antigen levels. Dosing with ARB-1467 in Cohort 4 has been generally well tolerated, with no serious adverse events. Eleven of background: -o-linear-gradient(top, #ededed 0%,#cdcdcd 100%); the twelve patients received all five bi-weekly doses. ALT values remained normal throughout treatment. Detailed results of Cohort 4 are expected to .bottom_bg{height:44px; background:#181818; margin-top:34px} be presented at AASLD in October.

“The new Phase II results for ARB-1467 show greater reduction in serum HBsAg levels with a favorable safety profile. We look forward to .bottom_rs{width:960px; height:44px; overflow:hidden; margin:0 auto; position:relative} presenting detailed bi-weekly dosing results at AASLD,” said Dr. Mark J. Murray, Arbutus’ President and Humspm.com CEO. “Furthermore, we are planning to .bottom_rs h3{float:left; width:auto; font-size:13px; color:#ababab; line-height:44px; text-transform:capitalize;padding-left:8px} initiate a new study of ARB-1467 in 4Q17 to evaluate longer dosing of background: -ms-linear-gradient(top, #ededed 0%,#cdcdcd 100%); ARB-1467 combined with interferon. The design of background: linear-gradient(to bottom, #ededed 0%,#cdcdcd 100%); the study is box-shadow: 0px 1px 10px 0px rgba(0,0,0,0.75);} informed by the .leftblk{float:left; overflow:hidden} findings in Cohort 4 and has the .leftblk img{float: left; margin-top:22px; *margin-top:18px; padding-right: 15px;} potential to .bottom_rs ul{float:left; width:785px; height:44px; overflow:hidden;list-style:none} create a late stage development and possible approval pathway for ARB-1467.”

ARB-1467 Phase 2 Trial Design
The Phase II trial is .footerwrap{width:960px; margin:0 auto;} a multi-dose study in chronic HBV patients who are also receiving stable nucleot(s)ide analog therapy. The trial consists of filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ededed', endColorstr='#cdcdcd',GradientType=0 ); _background: #ededed} four cohorts, the first three of which enrolled eight subjects each (six receiving three monthly doses of ARB-1467 and two receiving placebo) and the .domain_name{float:left; line-height:34px; font-size:26px; font-weight: normal; color:#fff; padding-top:27px; width:535px} fourth enrolled twelve patients (all of .content{background:#483d5b; -webkit-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); whom were to .bottom_rs ul li{float:left; list-style:none; line-height:44px; padding-left:13px} receive 5 bi-weekly doses of ARB-1467, followed by monthly dosing for patients who met predefined response criteria). Cohorts 1, 2, and 4 included HBeAg- patients and Cohort 3 included HBeAg+ patients.

Next Steps for ARB-1467
Arbutus will initiate a new study in 4Q17 to study longer term bi-weekly dosing of ARB-1467 in combination with tenofovir followed by the addition of -moz-box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75); pegylated interferon for patients who meet a predefined response criteria. This study will explore the #logo{float:right;width:300px;padding:15px 0 0} effect of .kwd_bloack{float:left; width:514px; margin-top:50px} box-shadow: 0px -1px 10px 0px rgba(0,0,0,0.75);} driving HBsAg to very low levels with ARB-1467 along with an immune modulating mechanism.

About ARB-1467
Arbutus’ RNAi candidate ARB-1467 comprises three RNAi triggers that target all four HBV transcripts, and has been shown in preclinical studies to .bottom_rs ul li a{float:left; font-size:16px; text-decoration:underline; color:#079ce9} reduce all viral antigen levels as well as cccDNA and HBV DNA. ARB-1467 utilizes Arbutus’ proprietary lipid nanoparticle (LNP) platform, a clinically validated delivery technology, which has been tested in hundreds of .frt_arr{float:left;width:223px; height:503px; background-position:0 3px; background-repeat:no-repeat} patients.

About Arbutus
Arbutus Biopharma Corporation is #footer-keys-bot span{color:#fff; font-weight:bold; font-size:15px} a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is #footer-keys-bot p{text-align:left; padding:0 10px} headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Forward-Looking Statements and